USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
04-Feb-2014
North America
Market Research
MA14-01-00-00-00
LS00099-NA-MR_16940
This research service focuses on existing therapeutics and product pipeline for the treatment of Parkinson’s Disease using Dopamine Replacement Therapies, Dopamine Agonists, MAO-inhibitors, COMT-inhibitors and other pharamcolgical approaches for current global interest. This research service does not cover vaccines. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for Parkinson’s Disease therapeutics. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.
Executive Summary
Recent Market Developments
Companies to Watch
Key Trends in Parkinson’s Disease Therapeutics
Methodology and Scope
Introduction
Global Prevalence of Parkinson’s Disease by Country
Global Incidence of Parkinson’s Disease by Country
Market Overview—Segmentation by Types of Therapeutics
Market Overview—Segmentation Illustrated
Market Overview—Segmentation Illustrated (continued)
Overview of Market Opportunities
Competitive Landscape—Marketed Products and Products in Development
Marketed Product Synopsis—Parkinson’s Disease Therapeutics
Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)
Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)
Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued)
Pipeline Synopsis—Parkinson’s Disease Therapeutics
Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued
Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued
Pipeline Synopsis—Parkinson’s Disease Therapeutics- Continued
Parkinson’s Disease Therapeutics Market—Competitive Landscape: Major Ongoing Trials
Competitive Landscape—Projected Launch Timeline for Key Pipeline Drugs
Competitive Landscape—Company Assets by Drug Pipeline Class
Key Marketed Products Dashboard: Stalevo (Carbidopa-Levodopa-Entacapone)—Orion Corporation
Key Marketed Products Dashboard: Sinemet (carbidopa-levodopa)—Merck & Co
Key Marketed Products Dashboard: Azilect (Rasagiline) By TEVA Pharmaceuticals
Key Marketed Products Dashboard: Zelapar (Selagiline) By Valeant Pharmaceuticals
Key Marketed Products Dashboard: Mirapex (Pramipexole) By Boehringer Ingelheim
Key Marketed Products Dashboard: Neupro (Rotigotine) By UCB Inc. and Schwarz Pharma
Key Marketed Products Dashboard: Requip (Ropinirole) By Glaxo SmithKline
Key Phase 3 Products Dashboard:Nouriast® (Istradefylline) By Kyowa Hakko Kirin
Key Phase 2 Products Dashboard:Ampyra® (dalfampridine) By Acorda Therapeutics
Key Phase 3 Products Dashboard:Duodopa® (sinemet) By AbbVie Pharmaceutical
Conclusion
Conclusions (Continued)
Legal Disclaimer
Decision Support Database—Global Population with Parkinson’s Disease
Decision Support Database—Global Population with Parkinson’s Disease (continued)
Who is Frost & Sullivan
What Makes Us Unique
TEAM Methodology
Our Global Footprint 40+ Offices
Speak directly with our analytics experts for tailored recommendations.
Recent related Life Sciences research
13 Jan 2025 | Global | Market Outlook
Top 6 Growth Opportunities for the Digital Health Industry, 2025
Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...
17 Dec 2024 | Global | Market Research
Cybersecurity in Healthcare, United States, 2024
Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...
12 Dec 2024 | Global | Market Outlook
Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025
Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...
05 Dec 2024 | Global | Frost Radar
Frost Radar™: Enterprise Conversational AI in Healthcare, 2024
This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...
27 Nov 2024 | Global | Market Research
Generative AI in Payer and Provider IT Transformation, Global, 2024-2029
The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Market Research |
|---|---|
| No Index | No |
| Podcast | No |
| WIP Number | MA14-01-00-00-00 |
| Is Prebook | No |
Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market
$3,950.00
Special Price $2,962.50 save 25 %